Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [1][13] - The company was founded in 2008 with a vision to transform the treatment of endocrine diseases [1] Lead Drug Candidate - The lead drug candidate, paltusotine, is on track for a New Drug Application submission with the U.S. Food and Drug Administration (FDA) by the end of 2024 [1] - Paltusotine is a first-in-class, oral somatostatin receptor type 2 (SST2) agonist currently in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors [13] Pipeline and Drug Development - Crinetics has a deep pipeline of internally discovered drug candidates, including atumelnant (CRN04894), an oral ACTH antagonist completing Phase 2 clinical studies for congenital adrenal hyperplasia and Cushing's disease [13] - The company is also developing treatments for various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity [13] Leadership Recognition - Scott Struthers, Ph.D., founder and CEO of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner, recognizing his leadership and the company's growth [14][15] - As a regional award winner, Dr. Struthers is eligible for the National Awards, with winners announced in November at the Strategic Growth Forum® [15]

Core Insights - Scott Struthers, Ph.D., founder and CEO of Crinetics Pharmaceuticals, has been awarded the Entrepreneur Of The Year® 2024 Pacific Southwest Award, recognizing his leadership in high-growth companies [1][4]. Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [3][16]. - The company was founded in 2008 and has grown to over 300 employees, emphasizing a collaborative approach to innovation in treatment [3]. - Crinetics is advancing its lead drug candidate, paltusotine, which is expected to submit a New Drug Application to the FDA by the end of 2024 [3][16]. - The company has a robust pipeline of internally discovered drug candidates targeting various endocrine conditions, including acromegaly and congenital adrenal hyperplasia [16]. Awards and Recognition - As a Pacific Southwest award winner, Dr. Struthers is eligible for the Entrepreneur Of The Year 2024 National Awards, with winners announced in November [4]. - The Entrepreneur Of The Year program has recognized over 11,000 entrepreneurs since its inception in 1986, expanding to nearly 80 countries [8].

"The depth and breadth of our clinical development program for once-daily, oral paltusotine under investigation for the treatment of acromegaly is on display at ENDO 2024, demonstrating its rapid, durable effect on both biochemical and symptom control in these studies," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "Notably, based on patient reported outcome data captured daily by the Acromegaly Symptom Diary, a new analysis from the PATHFNDR-1 trial showed that paltusotine ...

Core Insights - Crinetics Pharmaceuticals announced promising initial findings from its clinical product candidate, atumelnant (CRN04894), a novel oral ACTH receptor antagonist, during the Endocrine Society's annual meeting (ENDO2024) [1][2] Group 1: Clinical Trial Results - In the Phase 2 TouCAHn study, participants with congenital adrenal hyperplasia (CAH) showed over 90% reduction in androstenedione (A4) and 97% reduction in 17-hydroxyprogesterone (17-OHP) after 12 weeks of treatment with atumelnant (80 mg) [1][3] - 100% of CAH participants maintained A4 levels below the upper limit of normal at all time points during the treatment [1][3] - The Phase 1b/2a study for ACTH-dependent Cushing's syndrome demonstrated that 100% of participants achieved serum cortisol levels below 5 mcg/dL within 10 days of atumelnant administration [6][9] Group 2: Safety and Tolerability - No severe or serious treatment-emergent adverse events were reported in the ongoing trials, with all adverse events being mild to moderate [4][6] - The most common treatment-emergent adverse events included fatigue, headache, and upper respiratory tract infection [4][6] Group 3: Mechanism and Significance - Atumelnant is the first once-daily oral ACTH receptor antagonist, which directly inhibits ACTH at its receptor, offering a novel approach compared to traditional glucocorticoid treatments [2][5] - The drug has shown strong binding affinity for the melanocortin type 2 receptor (MC2R) and effectively suppresses adrenally derived glucocorticoids and androgens [11] Group 4: Future Developments - The TouCAHn study aims to enroll up to 30 patients and is ongoing, with topline results expected in the second half of 2024 [12] - Crinetics will host an investor conference call to discuss these findings further [7]

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the ...

Core Insights - Crinetics Pharmaceuticals has appointed Dr. Robert M. Cuddihy as senior vice president of Medical Affairs, bringing over 30 years of experience in endocrinology and pharmaceutical medical affairs [1][2] - Dr. Cuddihy will play a crucial role in the development and potential commercialization of investigational product candidates, including paltusotine and atumelnant, which target high unmet needs in endocrine diseases [2] - The company is focused on developing novel therapeutics for endocrine diseases and related tumors, with paltusotine in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome, while atumelnant is completing Phase 2 studies for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [3] Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for endocrine diseases [3] - The company's drug candidates are all orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, addressing various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity [3]

Core Insights - Crinetics Pharmaceuticals, Inc. announced the early release of late-breaking abstracts for presentation at the Endocrine Society's annual meeting (ENDO 2024) [1] Group 1: Clinical Studies - The Phase 2, open-label study of atumelnant (CRN04894) in Congenital Adrenal Hyperplasia will present summary data for four subjects, with plans to include additional data from a total of six subjects in cohort 1 and more in cohort 2 at ENDO 2024 [2] - A more comprehensive data set will be shared during the Late-Breaking Poster Presentation session scheduled for June 3, 2024, from 12:00 to 1:30 pm ET [2] Group 2: Company Overview - Crinetics Pharmaceuticals is focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and related tumors [3] - The company is developing paltusotine, an oral somatostatin receptor type 2 (SST2) agonist, currently in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome associated with neuroendocrine tumors [3] - Atumelnant (CRN04894) is an oral ACTH antagonist in Phase 2 studies for congenital adrenal hyperplasia and Cushing's disease [3] - All drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, targeting various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity [3]

Financial Data and Key Metrics Changes - The company ended Q1 2024 with approximately $900 million in cash and investments, bolstered by a $350 million private placement in February [18][36] - Research and development expenses increased to $53.3 million in Q1 2024 from $38.5 million in Q1 2023, primarily due to higher personnel costs and development activities [37] - Revenues decreased to $0.6 million in Q1 2024 from $2.7 million in Q1 2023, with current revenues mainly from a licensing arrangement for Paltusotine [38] - General and administrative expenses rose to $20.8 million in Q1 2024 from $12.2 million in Q1 2023, attributed to higher personnel costs [61] - The net loss for Q1 2024 was $66.9 million, compared to a net loss of $46 million in Q1 2023 [61] - Net cash used for operating activities was $52.9 million in Q1 2024, with an expected cash burn of $50 million to $60 million per quarter for the remainder of 2024 [62] Business Line Data and Key Metrics Changes - The company reported positive results from late-stage clinical studies for Paltusotine in patients with acromegaly and carcinoid syndrome, supporting its potential NDA filing [9][16] - Paltusotine demonstrated significant improvements in acromegaly symptom control and rapid IGF-1 response, which could allow faster dose optimization compared to current treatments [53] - Atumelnant, the second investigational compound, is in development for CAH and Cushing's disease, with initial data expected to be presented at the upcoming Endocrine Society meeting [55][59] Market Data and Key Metrics Changes - The company is actively engaging with leading payers to understand market dynamics for Paltusotine, which has received positive feedback from early discussions [26] - There is a significant population of patients with carcinoid syndrome who are currently untreated, presenting a unique market opportunity for Paltusotine [131] Company Strategy and Development Direction - The company aims to advance Paltusotine towards regulatory submissions and continue developing its pipeline, including Atumelnant and other early-stage programs [39][60] - A campaign will be launched to increase awareness among healthcare providers about the unmet needs in current treatments for acromegaly and carcinoid syndrome [25] - The company plans to align with the FDA on Phase 3 study designs for both carcinoid syndrome and CAH, with a focus on addressing the limitations of current therapies [49][80] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong progress made in Q1 2024 and anticipates multiple upcoming milestones from clinical candidates [39][50] - The company is committed to investing in its discovery capabilities to ensure long-term success and address higher prevalence indications [50] Other Important Information - The company will present five abstracts at the ENDO Conference, including late-breaking data from clinical studies of Atumelnant [11] - The PATHFNDR Phase 3 program for acromegaly has met all primary and secondary endpoints, supporting the transition to regulatory filing [28] Q&A Session Summary Question: Insights on Cushing's data set - Management highlighted the importance of cortisol reduction in patients with Cushing's disease and expressed interest in the results from the ongoing study [41][42] Question: Satisfaction with Atumelnant's pharmacodynamics - Management indicated that satisfaction levels would be clearer after presenting data at the Endocrine Society meeting [45][47] Question: Phase 3 design for carcinoid syndrome - Management discussed the importance of measuring symptom frequency and severity in the Phase 3 trial, with sample sizes expected to be between 80 and 150 patients [80] Question: Feedback from physicians on Paltusotine - Positive feedback was received from physicians regarding the potential of Paltusotine to address the limitations of current injection therapies for carcinoid syndrome [108] Question: Commercialization overlap for CAH and acromegaly - There is a high degree of overlap in treatment centers and prescribers for CAH and acromegaly, which could facilitate commercialization efforts [137][138]

SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The stock options were granted as inducements material to th ...

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.71%. A quarter ago, it was expected that this company would post a loss of $0.89 per share when it actually produced a loss of $0.90, delivering a surprise of -1.12%.Over the last four quarters, the com ...